Synthesis and NK1 receptor antagonistic activity of (+/-)-1-acyl-3-(3,4- dichlorophenyl)-3-[2-(spiro-substituted piperidin-1'-yl)ethyl]piperidines. 1998

H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.

(+/-)-1-Acyl-3-(3,4-dichlorophenyl)-3-[2-(spiro-substituted piperidin-1'-yl)ethyl]piperidines and their quaternary ammonium salts were prepared and evaluated for their NK1 receptor antagonistic activity. Some of these inhibited SP-induced contraction in guinea pig ileum with IC50 values at a level of 10(-9) M and showed potent inhibitory activity against selective NK1 receptor agonist-induced bronchoconstriction in guinea pigs.

UI MeSH Term Description Entries
D007082 Ileum The distal and narrowest portion of the SMALL INTESTINE, between the JEJUNUM and the ILEOCECAL VALVE of the LARGE INTESTINE.
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D010880 Piperidines A family of hexahydropyridines.
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016084 Bronchoconstriction Narrowing of the caliber of the BRONCHI, physiologically or as a result of pharmacological intervention. Bronchial Constriction,Bronchial Constrictions,Bronchoconstrictions,Constriction, Bronchial,Constrictions, Bronchial
D064729 Neurokinin-1 Receptor Antagonists Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS. Neurokinin 1 Receptor Antagonist,Neurokinin-1 Receptor Antagonist,Neurokinin-1 Receptor Blocker,Neuroleukin-1 Receptor Blocker,Substance P Receptor Antagonist,Substance P Receptor Blocker,Tachykinin Receptor 1 Antagonist,Tachykinin Receptor 1 Blocker,Neurokinin-1 Receptor Blockers,Neuroleukin-1 Receptor Blockers,Substance P Receptor Antagonists,Substance P Receptor Blockers,Tachykinin Receptor 1 Antagonists,Tachykinin Receptor 1 Blockers,Antagonist, Neurokinin-1 Receptor,Antagonists, Neurokinin-1 Receptor,Blocker, Neurokinin-1 Receptor,Blocker, Neuroleukin-1 Receptor,Blockers, Neurokinin-1 Receptor,Blockers, Neuroleukin-1 Receptor,Neurokinin 1 Receptor Antagonists,Neurokinin 1 Receptor Blocker,Neurokinin 1 Receptor Blockers,Neuroleukin 1 Receptor Blocker,Neuroleukin 1 Receptor Blockers,Receptor Antagonist, Neurokinin-1,Receptor Antagonists, Neurokinin-1,Receptor Blocker, Neurokinin-1,Receptor Blocker, Neuroleukin-1,Receptor Blockers, Neurokinin-1,Receptor Blockers, Neuroleukin-1

Related Publications

H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
February 1998, Chemical & pharmaceutical bulletin,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
November 2002, Journal of medicinal chemistry,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
June 2013, European journal of medicinal chemistry,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
September 2005, Bioorganic & medicinal chemistry letters,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
September 2008, Acta crystallographica. Section E, Structure reports online,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
August 2008, Acta crystallographica. Section E, Structure reports online,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
October 1991, Journal of medicinal chemistry,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
January 2006, The Journal of organic chemistry,
H Kubota, and Y Okamoto, and M Fujii, and K Ikeda, and M Takeuchi, and T Shibanuma, and Y Isomura
October 2009, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!